Exact Mass: 1145.5604274
Exact Mass Matches: 1145.5604274
Found 23 metabolites which its exact mass value is equals to given mass value 1145.5604274,
within given mass tolerance error 0.05 dalton. Try search metabolite list with more accurate mass tolerance error
0.01 dalton.
CDP-DG(22:3(10Z,13Z,16Z)/PGF1alpha)
CDP-DG(22:3(10Z,13Z,16Z)/PGF1alpha) is an oxidized CDP-diacylglycerol (CDP-DG). Oxidized CDP-diacylglycerols are glycerophospholipids in which a cytidine diphosphate moiety occupies a glycerol substitution site and at least one of the fatty acyl chains has undergone oxidation. As all oxidized lipids, oxidized CDP-diacylglycerols belong to a group of biomolecules that have a role as signaling molecules. The biosynthesis of oxidized lipids is mediated by several enzymatic families, including cyclooxygenases (COX), lipoxygenases (LOX) and cytochrome P450s (CYP). Non-enzymatically oxidized lipids are produced by uncontrolled oxidation through free radicals and are considered harmful to human health (PMID: 33329396). As is the case with diacylglycerols, CDP-diacylglycerols can have many different combinations of fatty acids of varying lengths, saturation and degrees of oxidation attached at the C-1 and C-2 positions. CDP-DG(22:3(10Z,13Z,16Z)/PGF1alpha), in particular, consists of one chain of one 10Z,13Z,16Z-docosenoyl at the C-1 position and one chain of Prostaglandin F1alpha at the C-2 position. Phospholipids are ubiquitous in nature and are key components of the lipid bilayer of cells, as well as being involved in metabolism and signaling. Similarly to what occurs with phospholipids, the fatty acid distribution at the C-1 and C-2 positions of glycerol within oxidized phospholipids is continually in flux, owing to phospholipid degradation and the continuous phospholipid remodeling that occurs while these molecules are in membranes. Oxidized CDP-DGs can be synthesized via three different routes. In one route, the oxidized CDP-DG is synthetized de novo following the same mechanisms as for CDP-DGs but incorporating oxidized acyl chains (PMID: 33329396). An alternative is the transacylation of one of the non-oxidized acyl chains with an oxidized acylCoA (PMID: 33329396). The third pathway results from the oxidation of the acyl chain while still attached to the CDP-DG backbone, mainly through the action of LOX (PMID: 33329396).
CDP-DG(PGF1alpha/22:3(10Z,13Z,16Z))
CDP-DG(PGF1alpha/22:3(10Z,13Z,16Z)) is an oxidized CDP-diacylglycerol (CDP-DG). Oxidized CDP-diacylglycerols are glycerophospholipids in which a cytidine diphosphate moiety occupies a glycerol substitution site and at least one of the fatty acyl chains has undergone oxidation. As all oxidized lipids, oxidized CDP-diacylglycerols belong to a group of biomolecules that have a role as signaling molecules. The biosynthesis of oxidized lipids is mediated by several enzymatic families, including cyclooxygenases (COX), lipoxygenases (LOX) and cytochrome P450s (CYP). Non-enzymatically oxidized lipids are produced by uncontrolled oxidation through free radicals and are considered harmful to human health (PMID: 33329396). As is the case with diacylglycerols, CDP-diacylglycerols can have many different combinations of fatty acids of varying lengths, saturation and degrees of oxidation attached at the C-1 and C-2 positions. CDP-DG(PGF1alpha/22:3(10Z,13Z,16Z)), in particular, consists of one chain of one Prostaglandin F1alpha at the C-1 position and one chain of 10Z,13Z,16Z-docosenoyl at the C-2 position. Phospholipids are ubiquitous in nature and are key components of the lipid bilayer of cells, as well as being involved in metabolism and signaling. Similarly to what occurs with phospholipids, the fatty acid distribution at the C-1 and C-2 positions of glycerol within oxidized phospholipids is continually in flux, owing to phospholipid degradation and the continuous phospholipid remodeling that occurs while these molecules are in membranes. Oxidized CDP-DGs can be synthesized via three different routes. In one route, the oxidized CDP-DG is synthetized de novo following the same mechanisms as for CDP-DGs but incorporating oxidized acyl chains (PMID: 33329396). An alternative is the transacylation of one of the non-oxidized acyl chains with an oxidized acylCoA (PMID: 33329396). The third pathway results from the oxidation of the acyl chain while still attached to the CDP-DG backbone, mainly through the action of LOX (PMID: 33329396).
(5S,6S)-2-[[(3R,4S)-5-(aminomethyl)-3,4-dihydroxyoxolan-2-yl]oxy-[(3S,4R)-5-(3,5-dioxo-2H-pyrazin-2-yl)-3,4-dihydroxyoxolan-2-yl]methyl]-1,4-dimethyl-6-[3-[3-methyl-5-oxo-5-[(2S,3R,4R)-3,4,5-trimethoxy-6-methyloxan-2-yl]oxypentanoyl]oxyhexadecanoyloxy]-3-oxo-1,4-diazepane-5-carboxylic acid
C53H87N5O22 (1145.5842401999998)
(5S,6S)-2-[[(3R,4S)-5-(azaniumylmethyl)-3,4-dihydroxyoxolan-2-yl]oxy-[(3S,4R)-5-(3,5-dioxo-2H-pyrazin-2-yl)-3,4-dihydroxyoxolan-2-yl]methyl]-1,4-dimethyl-6-[3-[3-methyl-5-oxo-5-[(2S,3R,4R)-3,4,5-trimethoxy-6-methyloxan-2-yl]oxypentanoyl]oxyhexadecanoyloxy]-3-oxo-1,4-diazepane-5-carboxylate
C53H87N5O22 (1145.5842401999998)
Lys-[Des-Arg9]Bradykinin (TFA)
C52H74F3N13O13 (1145.5480870000001)
Lys-[Des-Arg9]Bradykinin TFA, a naturally occurring kinin, is a potent and highly selective bradykinin B1 receptor agonist with a Ki of 0.12 nM, 1.7 nM and 0.23 nM for human, mouse and rabbit B1 receptors, respectively. Lys-[Des-Arg9]Bradykinin TFA has low inhibitory activity on B2 receptors[1][2].
[(3s,6s,12s,15s,21s,24r,27s)-12-(carboxymethyl)-5,8,11,14,17,20,23,26-octahydroxy-24-[2-(c-hydroxycarbonimidoyl)ethyl]-15-(c-hydroxycarbonimidoylmethyl)-6-[(4-hydroxyphenyl)methyl]-27-[(1-hydroxytridecylidene)amino]-3-isopropyl-28-methyl-2-oxo-1-oxa-4,7,10,13,16,19,22,25-octaazacyclooctacosa-4,7,10,13,16,19,22,25-octaen-21-yl]acetic acid
n-{1-[(1-{[9-(2-chloro-3,5-dihydroxy-4-methylphenyl)-2,5,8,11-tetrahydroxy-13-methyl-6-(sec-butyl)-1,4,7,10-tetraazacyclotrideca-1,4,7,10-tetraen-12-yl]-c-hydroxycarbonimidoyl}ethyl)-c-hydroxycarbonimidoyl]-2-hydroxypropyl}-11-{[3,4-dihydroxy-6-(hydroxymethyl)-5-methoxyoxan-2-yl]oxy}-9,12-dihydroxy-4,6,8,10-tetramethyl-3-oxotridecanimidic acid
(8s,9r,10s,11s,12r)-n-[(1r,2r)-1-{[(1s)-1-{[(6s,9r,12r,13r)-6-[(2s)-butan-2-yl]-9-(2-chloro-3,5-dihydroxy-4-methylphenyl)-2,5,8,11-tetrahydroxy-13-methyl-1,4,7,10-tetraazacyclotrideca-1,4,7,10-tetraen-12-yl]-c-hydroxycarbonimidoyl}ethyl]-c-hydroxycarbonimidoyl}-2-hydroxypropyl]-11-{[(2r,3r,4r,5s,6r)-3,4-dihydroxy-6-(hydroxymethyl)-5-methoxyoxan-2-yl]oxy}-9,12-dihydroxy-4,6,8,10-tetramethyl-3-oxotridecanimidic acid
[12-(carboxymethyl)-5,8,11,14,17,20,23,26-octahydroxy-24-[2-(c-hydroxycarbonimidoyl)ethyl]-15-(c-hydroxycarbonimidoylmethyl)-6-[(4-hydroxyphenyl)methyl]-27-[(1-hydroxytridecylidene)amino]-3-isopropyl-28-methyl-2-oxo-1-oxa-4,7,10,13,16,19,22,25-octaazacyclooctacosa-4,7,10,13,16,19,22,25-octaen-21-yl]acetic acid
2-({[5-(aminomethyl)-3,4-dihydroxyoxolan-2-yl]oxy}[3,4-dihydroxy-5-(4-hydroxy-2-oxopyrimidin-1-yl)oxolan-2-yl]methyl)-1,4-dimethyl-6-{[14-methyl-3-({3-methyl-5-oxo-5-[(3,4,5-trimethoxy-6-methyloxan-2-yl)oxy]pentanoyl}oxy)pentadecanoyl]oxy}-3-oxo-1,4-diazepane-5-carboxylic acid
C53H87N5O22 (1145.5842401999998)
(2s,5s,6s)-2-({[(2s,3r,4s,5r)-5-(aminomethyl)-3,4-dihydroxyoxolan-2-yl]oxy}[(2s,3s,4r,5r)-3,4-dihydroxy-5-(4-hydroxy-2-oxopyrimidin-1-yl)oxolan-2-yl]methyl)-1,4-dimethyl-6-{[(3s)-3-{[(3s)-3-methyl-5-oxo-5-{[(2s,3r,4r,5r,6r)-3,4,5-trimethoxy-6-methyloxan-2-yl]oxy}pentanoyl]oxy}hexadecanoyl]oxy}-3-oxo-1,4-diazepane-5-carboxylic acid
C53H87N5O22 (1145.5842401999998)
(2s)-n-[(2s,5s,8s,11r,12s,15s)-5-benzyl-8-[(2s)-butan-2-yl]-6,13,16,21-tetrahydroxy-2-[(1r)-1-hydroxyethyl]-15-[(4-hydroxyphenyl)methyl]-4,11-dimethyl-3,9,22-trioxo-10-oxa-1,4,7,14,17-pentaazabicyclo[16.3.1]docosa-6,13,16-trien-12-yl]-2-{[(2s,3r)-2-{[1,2-dihydroxy-3-(4-hydroxyphenyl)propylidene]amino}-1,3-dihydroxybutylidene]amino}pentanediimidic acid
n-[5-benzyl-6,13,16,21-tetrahydroxy-2-(1-hydroxyethyl)-15-[(4-hydroxyphenyl)methyl]-4,11-dimethyl-3,9,22-trioxo-8-(sec-butyl)-10-oxa-1,4,7,14,17-pentaazabicyclo[16.3.1]docosa-6,13,16-trien-12-yl]-2-[(2-{[1,2-dihydroxy-3-(4-hydroxyphenyl)propylidene]amino}-1,3-dihydroxybutylidene)amino]pentanediimidic acid
(2s,5s,6s)-2-[(s)-{[(2s,3r,4s,5r)-5-(aminomethyl)-3,4-dihydroxyoxolan-2-yl]oxy}[(2s,3s,4r,5r)-3,4-dihydroxy-5-(4-hydroxy-2-oxopyrimidin-1-yl)oxolan-2-yl]methyl]-1,4-dimethyl-6-{[(3s)-14-methyl-3-{[(3s)-3-methyl-5-oxo-5-{[(2s,3r,4r,5s,6s)-3,4,5-trimethoxy-6-methyloxan-2-yl]oxy}pentanoyl]oxy}pentadecanoyl]oxy}-3-oxo-1,4-diazepane-5-carboxylic acid
C53H87N5O22 (1145.5842401999998)
(2s,6s)-2-[(r)-{[(2s,3r,4s,5r)-5-(aminomethyl)-3,4-dihydroxyoxolan-2-yl]oxy}[(2s,3s,4r,5r)-3,4-dihydroxy-5-(4-hydroxy-2-oxopyrimidin-1-yl)oxolan-2-yl]methyl]-1,4-dimethyl-6-{[(3s)-14-methyl-3-{[(3s)-3-methyl-5-oxo-5-{[(2s,3r,4r,5s,6s)-3,4,5-trimethoxy-6-methyloxan-2-yl]oxy}pentanoyl]oxy}pentadecanoyl]oxy}-3-oxo-1,4-diazepane-5-carboxylic acid
C53H87N5O22 (1145.5842401999998)
2-({[5-(aminomethyl)-3,4-dihydroxyoxolan-2-yl]oxy}[3,4-dihydroxy-5-(4-hydroxy-2-oxopyrimidin-1-yl)oxolan-2-yl]methyl)-1,4-dimethyl-6-{[3-({3-methyl-5-oxo-5-[(3,4,5-trimethoxy-6-methyloxan-2-yl)oxy]pentanoyl}oxy)hexadecanoyl]oxy}-3-oxo-1,4-diazepane-5-carboxylic acid
C53H87N5O22 (1145.5842401999998)